PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status

Fulton, B. et al. (2018) PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. Clinical and Translational Radiation Oncology, 8, pp. 12-16. (doi: 10.1016/j.ctro.2017.11.003)

[img]
Preview
Text
153362.pdf - Published Version
Available under License Creative Commons Attribution.

691kB

Abstract

Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform treatment schedules.

Item Type:Articles
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:Kelly, Mrs Caroline and Fulton, Ben and Nowicki, Dr Stefan and Morris, Miss Anna and James, Dr Allan and Stobo, Mr Jon and Chalmers, Professor Anthony
Authors: Fulton, B., Short, S. C., James, A., Nowicki, S., McBain, C., Jefferies, S., Kelly, C., Stobo, J., Morris, A., Williamson, A., and Chalmers, A.
College/School:College of Medical Veterinary and Life Sciences > Institute of Biodiversity Animal Health and Comparative Medicine
College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Journal Name:Clinical and Translational Radiation Oncology
Publisher:Elsevier
ISSN:2405-6308
ISSN (Online):2405-6308
Published Online:21 November 2017
Copyright Holders:Copyright © 2017 Elsevier Ireland Ltd.
First Published:First published in Clinical and Translational Radiation Oncology 8:12-16
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
703261PARADIGM-2: Olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in newly diagnosed glioblastoma stratified by MGMT status: 2 parallel phase I studiesAnthony ChalmersCancer Research UK (CRUK)20546ICS - CLINICAL TRIALS RESEARCH